Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata With or Without an Atopic Background From Two Randomized, Placebo-Controlled, Phase 3 Trials

The document presents the results of two phase 3 trials (BRAVE-AA1 and BRAVE-AA2) involving 1200 patients with severe alopecia areata (AA), 37.8% of whom had an atopic background. The trials tested the efficacy and safety of baricitinib, a medication for AA. At week 36, 40.8% of patients with an atopic background who received 4-mg baricitinib achieved a Severity of Alopecia Tool (SALT) score ≤20, compared to 30.2% of those without an atopic background. Improvements in eyebrow/eyelash measures were also observed. The safety profile of baricitinib was similar in both subgroups and the overall population. The study concludes that the safety and improvements in hair regrowth in baricitinib-treated patients with severe AA were independent of atopic background.